Kiranam Chatti

Principal Research Scientist

Research area :

  • Tyrosine kinase variants in cancer; Zebrafish as an alternate animal model for tyrosine kinase dysfunction and cancer

Education & Training :

  • 1998–2004: Ph.D. in Pharmacology & Toxicology, University of Mississippi Medical Center

Professional Experience :

  • 2005–2008: Post-doctoral fellow, State University of New York at Stony Brook
  • 2008–2013: Senior Research Scientist, Dr. Reddy’s Institute of Life Sciences
  • 2013-           : Principal Research Scientist, Dr. Reddy’s Institute of Life Sciences

Research Interests :

  • Tyrosine kinases are a major family of messengers in cell growth pathways. Drugs selectively inhibiting oncogenic tyrosine kinases (tyrosine kinase inhibitors or TKIs) have been shown to be clinically successful as targeted anti-cancer therapies. Access to TKIs in India and in several other countries is severely limited; evolution of drug resistance and occurrence of variant TKs is a problem. Kiranam Chatti’s work at DRILS is focused on-
    i) developing genetically engineered TK-mutant zebrafish as alternative animal models to facilitate in vivo evaluation of TKIs, and
    ii) using computational and experimental methods to study TK variants.
    Use of CRISPR-Cas9 technology as a tool to generate genetically modified zebrafish and cell lines is a recently initiated effort.

Link to Google Scholar page :